Our pharmaceutical group
“ONE CANNOT PRIORITIZE DISEASES. EVERY INDIVIDUAL IS PRICELESS."
Dr. Claudio Cavazza, Founder of the Sigma-Tau group
OUR MISSION: TO INNOVATE FOR THE SAKE OF HUMAN HEALTH.
SIGMA-TAU was founded in 1957. It has become one of the main Italian pharmaceutical groups with a worldwide presence, by combining research, successful products, industrial growth and ethics.
The mission of the SIGMA-TAU group is to improve the quality of life and human health. In order to honour this commitment and offer top-quality medicines, we invest heavily in:
- biopharmacological research,
- the continuous renewal of the technologic aspects of our production systems.
To find out more, go to: http://www.sigma-tau.it/ (research/missions)
RESEARCH: THE DRIVING FORCE IN OUR DEVELOPMENT.
Research, the main source of our efforts for innovation, enjoys continuous support from the company, as evidenced by the 16% share of our turnover dedicated to research. Our most recent areas of research include:
- the chemical and pharmacobiological study of carnitine and its derivatives, which are substances of natural origin particularly used to correct metabolic disorders in numerous pathologies,
- the development of new therapies in our traditional areas of expertise: cardiovascular, metabolic, gastrointestinal and central nervous system diseases,
- the development of innovative therapeutic solutions in oncology and autoimmune diseases.
In developing synthetic molecules and biotechnology medications, we are pursuing a dual objective: therapeutic efficacy and enhanced tolerability.
To find out more, go to: http://www.sigma-tau.it/ (research/activities and projects)
QUALITY: AN ETHICAL VALUE.
Every day the SIGMA-TAU group puts great emphasis on quality.
This methodological approach enables the company to develop medicines of very high quality.
To find out more, go to: http://www.sigma-tau.it/ (company/quality)
GROWTH: AIMING FOR AN INTERNATIONAL DIMENSION.
As early as the 1980’s Dr. Claudio Cavazza, Founder and current Chairman of the SIGMA-TAU group, decided to give the company an international dimension, offering innovative solutions in key therapeutic fields: Cardiology, Gastroenterology, Infectiology, Neurology, Oncology, Osteoporosis, Pneumology, Rheumatology, Urology.
To find out more about our subsidiaries worldwide, click on the world map.
SIGMA-TAU GROUP: KEY FIGURES
- 9 subsidiaries worldwide: USA, Germany, Spain, France, Netherlands, Portugal, United Kingdom, Switzerland and India, together with an international network of distribution under licence,
- 2441 staff members around the world, including 400 researchers within the Research and Development department,
- consolidated turnover of 616 million euros (2009),
- share of investment in research: 16% of turnover.
CONTACT DETAILS
SIGMA-TAU S.p.A.
Viale Shakespeare, 47
00144 Rome (Italy)
Telephone: +39.06.59 26 600
E-mail: corporate@sigma-tau.it
To find out more about the SIGMA-TAU group, visit http://www.sigma-tau.it/